Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
https://seekingalpha.com/article/4681344-nuvation-bio-strong-buy-off-acquisition-late-stage-lung-cancer-candidate?source=feed_tag_editors_picks
Mar 31, 2024 - Nuvation Bio's acquisition of taletrectinib, boosts market cap while ensuring years of independent funding with liquid assets. Read more on NUVB's prospects.
0
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO
https://seekingalpha.com/news/4085101-bayer-backed-boundless-bio-stock-falls-after-100m-ipo?source=feed_sector_healthcare
Mar 28, 2024 - Bayer-backed Boundless Bio (BOLD) saw its shares drop 8% following a $100M initial public offering on Thursday. Read more here.
0
Mustang Bio stock climbs 9% amid drug development update
https://seekingalpha.com/news/4085033-mustang-bio-stock-climbs-amid-drug-development-update?source=feed_sector_healthcare
Mar 28, 2024 - Mustang Bio (MBIO) stock rose 9% Thursday after the company said it was planning to expand testing of its oncology drug candidate MB-106 into autoimmune diseases. Read more here.
0
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
https://www.zacks.com/stock/news/2246863/kronos-bio-kron-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246863
Mar 27, 2024 - Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
What Makes Instil Bio (TIL) a New Buy Stock
https://www.zacks.com/stock/news/2246872/what-makes-instil-bio-til-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246872
Mar 27, 2024 - Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
https://www.zacks.com/stock/news/2246798/why-is-theravance-bio-tbph-down-9-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2246798
Mar 27, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
https://www.zacks.com/stock/news/2246721/earnings-preview-bluebird-bio-blue-q4-earnings-expected-to-decline?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2246721
Mar 27, 2024 - Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
bluebird bio falls as accounting errors force restatements
https://seekingalpha.com/news/4083728-bluebird-bio-stock-falls-accounting-errors?source=feed_sector_healthcare
Mar 26, 2024 - bluebird bio (BLUE) faces a significant stock drop after revealing accounting errors that force it to restate financials for 2022 and 2023. Read more here.
0
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
https://www.zacks.com/stock/news/2245547/opko-health-opk-and-entera-bio-announce-data-for-glp-2?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245547
Mar 25, 2024 - OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
0
bluebird bio Is Priced Below IP Value
https://seekingalpha.com/article/4680031-bluebird-bio-is-priced-below-ip-value?source=feed_all_articles
Mar 22, 2024 - bluebird bio's stock plummeted by 64% on safety concerns and high pricing for sickle cell treatment. Read why its potential sale value remains higher than its market cap.
0